The Microbiome Therapeutics Landscape in 2025: Current Dynamics and Future Direction
The 2025 Microbiome Landscape Review provides a clear, data-driven snapshot of how the microbiome therapeutics field is evolving, integrating insights across drug development, clinical progress, modality innovation, and competitive activity.
As of January 2026, Beacon Microbiome identifies 1,365 drugs within the microbiome therapeutic space. Covering both established and emerging therapeutic approaches, the review assesses pipeline expansion, competitive intensity, and areas of increasing differentiation across modalities and indications.
In the preclinical space, live biotherapeutic products (LBPs) account for 51% of active assets, while microbiome-sourced molecules represent 21% and molecule-based drugs 35%, reflecting growing interest in defined, scalable formats. The review also highlights expanding focus in IBD and inflammatory diseases, steady phase 2 progression, $6.8B in 2025 deal value, geographic shifts in trials, and key regulatory milestones – signalling increasing clinical and commercial maturity.
Download the Full Report Now
This Report Includes
The Drug Landscape
Explore a microbiome pipeline of 1,365+ assets, shaped by the continued dominance of live biotherapeutic products and growing momentum behind microbiome-sourced and defined molecule-based approaches.
The Trial Landscape
Track over 1,291 microbiome trials, with 146 new studies initiated in 2025 and steady post-COVID growth expected to drive 150–160 additional trial starts in 2026.
The Commercial Landscape
Uncover a dynamic microbiome company and deal landscape, with $6.8B in total deal value in 2025, reflecting rising strategic investment as the expanding microbiome market gains traction across therapeutics and adjacent industries.
The Future of the Microbiome Space
Examine how pivotal regulatory milestones are reshaping microbiome development, as the MAA submission of Xervyteg positions the field for its first non-CDI therapy and first EMA approval in over two years, alongside emerging expansion into transplant applications and growing interest in the ocular surface microbiota.
Regulatory Announcements
Review the regulatory momentum in microbiome therapeutics, highlighting a broad mix of IND/CTA approvals, MAA submissions, orphan designations, and breakthrough therapy updates in 2025, signalling continued clinical and regulatory advancement across the space.
Previous Microbiome Landscape Reviews
2024 Microbiome Landscape Review
2024 H1 Microbiome Landscape Review
You May Also Be Interested In…
Learn More About Microbiome
- The Most Comprehensive Way to Search the Microbiome Drug Development Landscape: Unique search ontologies based on Microbiome drug and trial characteristics
- Market Leading Approach to Microbiome Preclinical & Clinical Data Curation: Manual curation of key Microbiome research and development data points by Microbiome research scientists
- Seamlessly Integrate Commercial & Scientific Data all in One Place: Search Microbiome company and deal data based on their pipeline and technologies.
- Unrivalled Granularity in Reports & Analysis: Our search ontology and technology indexing enable comprehensive analysis not seen elsewhere.
What is Beacon?
Beacon is a world leading data analysis tool for preclinical and clinical trial information. With unrivalled granularity of search function, data quality, and exhaustiveness, Beacon provides timely information and gives you confidence to progress your targeted drug therapies to patients.
Learn more about how our clinical trials and drug database solutions can be tailored to your research requirements
